Pharmacogenetics in Lung Transplant Patients


About this study

The purpose of this study is to:

  • Demonstrate pharmacogenetic variability in the Mayo Clinic Florida lung transplant population.
  • Describe patterns in tacrolimus levels in the context of pharmacogenomic profiles
  • Use pharmacogenomic data to establish a need for therapeutic drug monitoring in selected other drugs
  • Use pharmacogenomic data, in combination with knowledge of drug interactions, to establish sensitivity to tacrolimus dose changes

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • First time lung transplant recipients at Mayo Clinic Florida that are prescribed Tacrolimus as part of their immunosuppression regimen

Exclusion Criteria: 

  • Recipients of a second lung transplant
  • Recipients of multiple organ transplants

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Jorge Mallea, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer